Selonsertib in Adults With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on
pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in
adults with pulmonary arterial hypertension (PAH). The study will consist of a 24-week
placebo-controlled treatment period and a long-term selonsertib treatment period.
Participants completing the 24-week placebo-controlled period will be eligible to receive
active treatment with selonsertib in the long-term treatment period.